Welcome To The Stem Cell Therapeutics HUB On AGORACOM

Stem Cell is a public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Free
Message: NR: SSS announces resignation of a BoD

Stem Cell Therapeutics Corp. Announces the Resignation of a Board of Director

CALGARY, ALBERTA, Sep 15, 2010 (MARKETWIRE via COMTEX News Network) --

Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) announced today that Scott Tannas will leave the board on September 30th, 2010.

Dean Peterson, SCT Chairman said "we thank Scott for his service to the company, and agree that now is the right time to reduce the size of our board. We have a "hands - on agenda" in front of us, and we feel confident we can move forward with current incumbents."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Share
New Message
Please login to post a reply